Wednesday, August 27, 2025

Revive Therapeutics Closes $23.0 Million Bought Deal Financing

Revive Therapeutics (CSE: RVV) this morning announced the closing of its bought deal financing. Originally announced at a figure of $10.0 million, strong demand lead to it being doubled to $20.0 million, before closing out today at $23.0 million with the exercise of the over-allotment option.

The financing saw units of the company sold at a price of $0.50 per each, with each unit containing one common share and one common share purchase warrant. Each warrant is valid for a period of three years and contains an exercise price of $0.70 per share.

An acceleration clause is also present on the warrant, enabling the company to accelerate the expiry date in the event that the equity trades above $1.10 for ten consecutive days on a volume weighted basis.

Net proceeds from the offering are to be used for phase 3 clinical costs for its study on the use of Bucillamine in the treatment of mild to moderate COVID-19, phase 1 clinical costs for the firms psilocybin for methamphetamine use disorder study, and other psychedelic formulation development work, as well as working capital and general corporate purposes.

Revive Therapeutics last traded at $0.65 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

Nord Precious Metals Identifies 29 Veins At Castle East Following 3D Modeling

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

Related News

Revive Therapeutics Reports Successful Results Using Psilocybin To Treat Traumatic Brain Injury

Revive Therapeutics (CSE: RVV) this morning revealed that it has received positive results for a...

Friday, March 19, 2021, 07:47:09 AM

Revive Submits for IRB Approval; Expects to Enroll Patients in September

This morning Revive Therapeutics (CSE: RVV, USA: RVVTF) announced they have submitted a clinical trial...

Wednesday, August 26, 2020, 10:07:43 AM

PharmaTher, Revive, Complete Psilocybin Intellectual Property Transaction

PharmaTher (CSE: PHRM) has seen the completion of the sale of its psilocybin program to...

Wednesday, February 17, 2021, 09:58:18 AM

Revive Files IND Application With FDA For Phase 3 Clinical Study For COVID-19 Treatment

Revive Therapeutics (CSE: RVV) announced after the bell today that it has officially filed its...

Tuesday, June 30, 2020, 07:18:46 PM

Revive Therapeutics Announces Final Stages In Bucillamine Phase 3 Clinical Trial For COVID-19

Revive Therapeutics (CSE: RVV) provided on Tuesday updates regarding the phase 3 clinical trial for oral...

Wednesday, January 19, 2022, 09:28:00 AM